Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
- PMID: 37429084
- DOI: 10.1016/j.ejmech.2023.115594
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Abstract
Histone deacetylase 8 (HDAC8) aberrantly deacetylates histone and non-histone proteins. These include structural maintenance of chromosome 3 (SMC3) cohesin protein, retinoic acid induced 1 (RAI1), p53, etc and thus, regulating diverse processes such as leukemic stem cell (LSC) transformation and maintenance. HDAC8, one of the crucial HDACs, affects the gene silencing process in solid and hematological cancer progressions especially on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). A specific HDAC8 inhibitor PCI-34051 showed promising results against both T-cell lymphoma and AML. Here, we summarize the role of HDAC8 in hematological malignancies, especially in AML and ALL. This article also introduces the structure/function of HDAC8 and a special attention has been paid to address the HDAC8 enzyme selectivity issue in hematological cancer especially against AML and ALL.
Keywords: Cancer; Enzyme selectivity; HDAC; HDAC8 inhibitor; Hematological malignancy.
Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no conflict of interests.
Similar articles
-
HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.Cell Stem Cell. 2015 Nov 5;17(5):597-610. doi: 10.1016/j.stem.2015.08.004. Epub 2015 Sep 18. Cell Stem Cell. 2015. PMID: 26387755 Free PMC article.
-
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.Blood. 2020 Apr 23;135(17):1472-1483. doi: 10.1182/blood.2019003538. Blood. 2020. PMID: 32315388
-
Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.Pharmacol Res. 2018 May;131:128-142. doi: 10.1016/j.phrs.2018.03.001. Epub 2018 Mar 4. Pharmacol Res. 2018. PMID: 29514055 Review.
-
Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.Pharm Pat Anal. 2018 Nov;7(6):259-276. doi: 10.4155/ppa-2018-0019. Epub 2019 Jan 11. Pharm Pat Anal. 2018. PMID: 30632447 Review.
-
HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia.Front Cell Dev Biol. 2020 Sep 4;8:844. doi: 10.3389/fcell.2020.00844. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33015043 Free PMC article.
Cited by
-
The Nutriepigenome.Genes (Basel). 2023 Oct 25;14(11):1997. doi: 10.3390/genes14111997. Genes (Basel). 2023. PMID: 38002940 Free PMC article. Review.
-
Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia.Ther Adv Hematol. 2024 Oct 16;15:20406207241283277. doi: 10.1177/20406207241283277. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39421716 Free PMC article. Review.
-
HDAC9 as a Privileged Target: Reviewing its Role in Different Diseases and Structure-activity Relationships (SARs) of its Inhibitors.Mini Rev Med Chem. 2024;24(7):767-784. doi: 10.2174/0113895575267301230919165827. Mini Rev Med Chem. 2024. PMID: 37818566 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
